| Wilkins, Victoria |
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome |
|
|
| Recruiting | 3 | 150 | US | BPN14770/ zatolmilast, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 06/25 | 09/25 | | |
| Recruiting | 3 | 250 | Europe, US, RoW | ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo | Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc. | Fragile X Syndrome | 05/25 | 05/25 | | |
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome |
|
|
| Recruiting | 2/3 | 150 | US | zatolmilast, BPN14770, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 09/25 | 12/25 | | |
| Yazdani, Hina |
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome |
|
|
| Recruiting | 3 | 150 | US | BPN14770/ zatolmilast, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 06/25 | 09/25 | | |
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome |
|
|
| Recruiting | 2/3 | 150 | US | zatolmilast, BPN14770, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 09/25 | 12/25 | | |
| Recruiting | N/A | 1500 | US | | Icahn School of Medicine at Mount Sinai | Acute Porphyrias, Cutaneous Porphyrias | 06/25 | 06/25 | | |
| Straley, Carly |
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome |
|
|
| Recruiting | 3 | 150 | US | BPN14770/ zatolmilast, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 06/25 | 09/25 | | |
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome |
|
|
| Recruiting | 2/3 | 150 | US | zatolmilast, BPN14770, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 09/25 | 12/25 | | |
NCT04873869 / 2020-003140-83: Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) |
|
|
| Recruiting | 2 | 52 | US | NBI-921352, Placebo | Neurocrine Biosciences | SCN8A Developmental and Epileptic Encephalopathy Syndrome | 12/25 | 12/25 | | |
EVOLVE, NCT04195568: Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System |
|
|
| Active, not recruiting | N/A | 248 | Canada, US, RoW | Surpass Evolve Flow Diverter System | Stryker Neurovascular | Aneurysm, Intracranial | 12/24 | 09/28 | | |
| Genovese, Ann |
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome |
|
|
| Recruiting | 3 | 150 | US | BPN14770/ zatolmilast, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 06/25 | 09/25 | | |
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome |
|
|
| Recruiting | 2/3 | 150 | US | zatolmilast, BPN14770, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 09/25 | 12/25 | | |
NCT05999240: Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder |
|
|
| Not yet recruiting | 2 | 30 | US | Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID], Nuzplazid, Placebo | New York State Psychiatric Institute, ACADIA Pharmaceuticals Inc., University of Kansas Medical Center, Research Foundation for Mental Hygiene, Inc., Weill Medical College of Cornell University | Autism Spectrum Disorder | 05/26 | 05/26 | | |
| Halaguena, Maria |
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome |
|
|
| Recruiting | 3 | 150 | US | BPN14770/ zatolmilast, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 06/25 | 09/25 | | |
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome |
|
|
| Recruiting | 2/3 | 150 | US | zatolmilast, BPN14770, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 09/25 | 12/25 | | |
